Abstract

Stroke is one of the most leading causes of death and disability in the world. Complement system activation contributes to pathogenesis and neuronal damage following stroke. There are no defined biological serum markers to determine the severity of stroke in acute phases. The purpose of current study was to determine the association of three complement activators, namely Pentraxin-3 (PTX3), M-ficolin, and Surfactant protein A (SPA) with the severity of ischemic stroke. This cross-sectional study was done on 82 patients diagnosed with ischemic stroke at 2496 hours of initiation of the clinical symptoms during 2014-2015. The serum levels of PTX3, M-ficolin, and SPA were measured by enzyme-linked immunosorbent assay (ELISA). The patients were divided in three stroke severity groups according to modified National Institute of Health Stroke Scale mNIHSS. The results showed that the more severity of the stroke was, the higher serum levels of three evaluated molecules (p<0.001) were. The correlation of serum level of PTX3, M-ficolin, and SPA with stroke severity was 0.732, 0.736, and 0.731, respectively. There is a strong association between serum levels of PTX3, M-ficolin, and SPA with the severity of ischemic stroke. Clinically, such association may be considered to evaluate the severity of the ischemic stroke.